20 Medical Technology Advances: Medicine in the Future – Part II.

Nanorobots swimming in blood vessels, in silico clinical trials instead of experimenting with drugs on animals and people, remote brain surgeries with the help of 5G networks – the second part of our shortlist on some astonishing ideas and innovations that could give us a glimpse into the future of medicine is ready for you to digest. Here, we’re going beyond the first part with medical tricorders, the CRISPR/Cas-9 gene-editing method, and other futuristic medical technologies to watch for. 11) In silico clinical trials against testing drugs on animals As technologies transform every aspect of healthcare, medicine, and the pharma industry, the monstrous clinical trial enterprise cannot be left out either. One way to modernize the drug testing process is applying technologies to the traditional framework, for example through online platforms to seek out participants; while an alternative way is to build a completely new setting. Human organs-on-chips and in silico trials represent the second approach. Researchers of the Wyss Institute have been working on the first strand, human organs-on-chips for years. These microdevices lined by living human cells can mimic the microarchitecture and functions of human organs, and this makes them ideal for replacing clinical testing. Going one giant leap further, we arrive at in silico trials: no humans, no animals, not even a single cell is required, and yet the impact of any given therapy...
Source: The Medical Futurist - Category: Information Technology Authors: Tags: Artificial Intelligence E-Patients Future of Medicine Future of Pharma Genomics Health Sensors & Trackers 3d printing AI bioprinting blockchain clinical trials CRISPR digital digital health drug development genetics Innovat Source Type: blogs

Related Links:

ConclusionsThe presence of abnormal18F-FDG uptake adjacent to the ischial tuberosities together with findings at the peri-articular shoulder or interspinous bursa on whole-body PET/CT is highly sensitive and specific for a diagnosis of PMR.Trial registrationClinical Trial Registration: Australian New Zealand Clinical Trials Registry,http://www.anzctr.org.au, ACTRN1261400696695
Source: European Journal of Nuclear Medicine and Molecular Imaging - Category: Nuclear Medicine Source Type: research
ConclusionIn order to overcome those key challenges arising from CT datasets and solve some of the main problems existing in the current deep learning-based methods, we propose a novel unified CTumorGAN framework, which can be effectively generalized to address any kinds of tumor datasets with superior performance.
Source: European Journal of Nuclear Medicine and Molecular Imaging - Category: Nuclear Medicine Source Type: research
Missing Electronic Supplementary Materials.
Source: European Journal of Nuclear Medicine and Molecular Imaging - Category: Nuclear Medicine Source Type: research
While other health care providers were reporting losses of hundreds of thousands of dollars a day as patients stayed away from hospitals, the cancer treatment provider reported its best financial year.
Source: Arkansas Business - Health Care - Category: American Health Source Type: news
CONCLUSION: Our data suggested that combined therapy with monensin might be a useful strategy for preventing EMT-mediated acquired drug resistance. PMID: 32736704 [PubMed - as supplied by publisher]
Source: Biochemical and Biophysical Research communications - Category: Biochemistry Authors: Tags: Biochem Biophys Res Commun Source Type: research
A mutation found in esophageal cancer alters integrin β4 mRNA splicing. Biochem Biophys Res Commun. 2020 Aug 27;529(3):726-732 Authors: Kelly GT, Faraj R, Dai Z, Cress AE, Wang T Abstract Integrin β4 (CD104, mRNA: ITGβ4) contributes to anchoring cells to the extracellular matrix and is regulated in many cancer types where it contributes to tumor progression. One splice variant, integrin β4E, is poorly characterized. We extracted several mutations from tumor samples within ITGB4 near the splice site that controls ITGβ4E production, and computational analysis predicted six of th...
Source: Biochemical and Biophysical Research communications - Category: Biochemistry Authors: Tags: Biochem Biophys Res Commun Source Type: research
Dysferlin-deficient myotubes show tethering of different membrane compartments characterized by TMEM16E and DHPRα. Biochem Biophys Res Commun. 2020 Aug 27;529(3):720-725 Authors: Kubozono K, Mizuta K, Fujimoto S, Tran TT, Kamata N, Tobiume K Abstract TMEM16E deficiency has been shown to be responsible for human limb-girdle muscular dystrophy LGMD2L. We found that endogenous TMEM16E co-localized with caveolin-3 at cytoplasmic vesicular compartments in a myotube from C2C12 cells (C2C12 myotube) without forming a molecular complex. In contrast, a myotube from murine myoblastic dysferlin-defici...
Source: Biochemical and Biophysical Research communications - Category: Biochemistry Authors: Tags: Biochem Biophys Res Commun Source Type: research
This study aimed to investigate the stability and therapeutic efficacy of the modified LNA- and PNA-type anti-miRs in a murine prostate cancer model under various treatment conditions. After verifying the anti-cancer potential of anti-miR21 by targeting tumor suppressor PTEN, the potential of the modified LNA- and PNA-type anti-miR21s was compared in vitro and in vivo. We found that PNA-type anti-miR21 showed better stability and therapeutic efficacy in the xenografted mouse tumor model than the LNA-type anti-miR21. Furthermore, PNA-type anti-miR21 treatment showed reduced tumor metastasis. This study may serve a...
Source: Biochemical and Biophysical Research communications - Category: Biochemistry Authors: Tags: Biochem Biophys Res Commun Source Type: research
In conclusion, five different imatinib-resistant GIST cell lines including the EXOC2-AK7 fusion gene derived from GIST-R5 represent important research tools for the investigation of cancer cell mechanisms underlying drug resistance and genetic variation. Furthermore, our study may facilitate pre-clinical studies of new therapeutic strategies. PMID: 32736695 [PubMed - as supplied by publisher]
Source: Biochemical and Biophysical Research communications - Category: Biochemistry Authors: Tags: Biochem Biophys Res Commun Source Type: research
Abstract The anticancer antibiotic heptelidic acid is a sesquiterpene lactone produced by the beneficial plant fungus Trichoderma virens. This species has been separated into two strains, referred to as P and Q, based on its biosynthesis of secondary metabolites; notably, only P-strains were reported to produce heptelidic acid. While characterizing a Q-strain of T. virens containing a directed mutation in the non-ribosomal peptide synthetase encoding gene Tex7, the appearance of an unknown compound in anomalously large quantities was visualized by TLC. Using a combination of HPLC, LC-MS/MS, and NMR spectrosco...
Source: Biochemical and Biophysical Research communications - Category: Biochemistry Authors: Tags: Biochem Biophys Res Commun Source Type: research
More News: Appendicitis | Atrial Fibrillation | Babies | Babies Heart Conditions | Biology | Blogging | Brain | Brain Cancers | Cancer | Cancer & Oncology | Cancer Vaccines | Cardiology | Centers for Disease Control and Prevention (CDC) | Chemistry | China Health | Clinical Trials | Computers | Databases & Libraries | Decubitus Ulcer (bed sore) | Estonia Health | Gene Therapy | Genetics | Heart | Heart Transplant | Hospitals | Information Technology | Internet | Japan Health | Laboratory Medicine | Learning | Legislation | Liver | Liver Transplant | Lung Transplant | Malaria | Malaria Vaccine | Measles | Measles Vaccine | Medical Ethics | Men | Muscular Dystrophy | Nanotechnology | Neurology | Neuroscience | Neurosurgery | Outbreaks | Parasitic Diseases | Parasitology | PET Scan | Pharmaceuticals | Reflex Sympathetic Dystrophy | Science | Skin | Sleep Disorders | Sleep Medicine | Spain Health | Statistics | Sweden Health | Universities & Medical Training | Urology & Nephrology | Vaccines | Veterinary Vaccinations